About the Authors

Niklas Mattsson

niklas.mattsson@neuro.gu.se (NM); erik.portelius@neuro.gu.se (EP)

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Lawrence Rajendran

Affiliation Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research, University of Zurich, Zurich, Switzerland

Henrik Zetterberg

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Mikael Gustavsson

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Ulf Andreasson

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Maria Olsson

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Gunnar Brinkmalm

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Johan Lundkvist

Affiliation Innovative Medicines, Central Nervous System and Pain iMed, Department of Neuroscience, AstraZeneca R&D, Södertälje, Sweden

Laura H. Jacobson

Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland

Ludovic Perrot

Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland

Ulf Neumann

Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland

Herman Borghys

Affiliation Neuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium

Marc Mercken

Affiliation Neuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium

Deborah Dhuyvetter

Affiliation Neuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium

Fredrik Jeppsson

Affiliation Innovative Medicines, Central Nervous System and Pain iMed, Department of Neuroscience, AstraZeneca R&D, Södertälje, Sweden

Kaj Blennow

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Erik Portelius

niklas.mattsson@neuro.gu.se (NM); erik.portelius@neuro.gu.se (EP)

Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Competing Interests

The authors have read the journal's policy and have the following conflicts: JL and FP are employed by Astra Zeneca. LHJ, LP and UN are employed by Novartis. HB, MM and DD are employed by Janssen. Astra Zeneca patent: * AZ-20 International application WO2010/056196. Novartis patents: * NB-B4 WO2010/003976 A1, 14. Jan 2010 * NB-C8 WO2011/009943 A1, 27. Jan 2011 Janssen patents: * (Applied for) Beauchamp, Jeremy; Benardeau, Agnes; Hilpert, Hans; Migliorini, Cristiano; Riboulet, William; Wang, Haiyan. 2-Aminodihydro[1,3]thiazines as BACE 2 inhibitors and their preparation and use in the treatment of diabetes. PCT Int. Appl. (2011), 64pp. CODEN: PIXXD2 WO 2011029803 A1 20110317 CAN 154:361040 AN 2011:326345 CAPLUS * (Applied for) Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Kooriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko. Preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivatives and related compounds for treatment of Alzheimer's disease. PCT Int. Appl. (2008), 354pp. CODEN: PIXXD2 WO 2008133273 A1 20081106 CAN 149:534229 AN 2008:1339943 CAPLUS * (Granted in South Korea) Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Koriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko. Preparation of 2-aminodihydrothiazine derivatives as beta-secretase inhibitors. PCT Int. Appl. (2007), 330pp. CODEN: PIXXD2 WO 2007049532 A1 20070503 CAN 146:482079 AN 2007:485607 CAPLUS This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: EP NM KB HZ JL FJ LR LHJ LP UN HB MM DD. Performed the experiments: MO MG JL FJ LR LHJ LP UN HB MM DD GB EP. Analyzed the data: EP NM UA. Contributed reagents/materials/analysis tools: JL FJ LR LHJ LP UN HB MM DD UA. Wrote the paper: EP NM.